ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.

Ocio EM, Efebera YA, Hájek R, Straub J, Maisnar V, Eveillard JR, Karlin L, Mateos MV, Oriol A, Ribrag V, Richardson PG, Norin S, Obermüller J, Bakker NA, Pour L

Open source

DOI: 10.3324/haematol.2023.283490
Published: 2024 Mar 1
Container: Haematologica
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2023.283490,
  title = {ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.},
  author = {Ocio EM and Efebera YA and Hájek R and Straub J and Maisnar V and Eveillard JR and Karlin L and Mateos MV and Oriol A and Ribrag V and Richardson PG and Norin S and Obermüller J and Bakker NA and Pour L},
  year = {2024},
  journal = {Haematologica},
  doi = {10.3324/haematol.2023.283490},
  url = {https://doi.org/10.3324/haematol.2023.283490}
}

RIS

TY  - JOUR
TI  - ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
AU  - Ocio EM
AU  - Efebera YA
AU  - Hájek R
AU  - Straub J
AU  - Maisnar V
AU  - Eveillard JR
AU  - Karlin L
AU  - Mateos MV
AU  - Oriol A
AU  - Ribrag V
AU  - Richardson PG
AU  - Norin S
AU  - Obermüller J
AU  - Bakker NA
AU  - Pour L
PY  - 2024
JO  - Haematologica
DO  - 10.3324/haematol.2023.283490
UR  - https://doi.org/10.3324/haematol.2023.283490
ER  -

APA

EM, O., YA, E., R, H., J, S., V, M., JR, E., L, K., MV, M., A, O., V, R., PG, R., S, N., J, O., NA, B., & L, P. (2024). ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.. Haematologica. https://doi.org/10.3324/haematol.2023.283490

Source records

pubmed · retrieved 2026-09-25T22:28:24.655Z